Intermittent Docetaxel Non-inferior in 1-year Survival for Patients With CRPC

Share this content:
Intermittent docetaxel could be an option for patients with CRPC.
Intermittent docetaxel could be an option for patients with CRPC.

Intermittent docetaxel chemotherapy displayed non-inferiority in 1-year survival compared to continuous treatment for patients with castration-resistant prostate cancer (CRPC), according to a study presented at the American Society of Clinical Oncology (ASCO)'s 2016 meeting.1

In a randomized, phase 3 study, 187 patients were assigned to receive docetaxel for either 12 weeks followed by a pause until disease progression, or continuous treatment until discontinuation. Patients received the drug at a rate of 35 mg/m2 per week or 75mg/m2 every 3 weeks.

Of 156 eligible patients, 50% in each cohort, 1-year survival was 75.8% for those receiving intermittent treatment, and 72.6% for those receiving treatment continuously; median overall survival was 19.3 months versus 18.3, respectively (P = .535).

RELATED: Adjuvant Docetaxel Fails to Improve Biochemical DFS in High-risk Prostate Cancer

The authors noted that although intermittent treatment was non-inferior for 1-year survival, it was deemed inferior for overall survival. Nonetheless it was concluded that intermittent docetaxel was well-tolerated and could be an option for patients with CRPC. Differences in progression-free survival and time to treatment failure were not significant between the 2 cohorts; safety profiles were comparable.

Reference

  1. Cash H, Steiner U, Heidenreich A, Klotz T, Melchior S, Albers P, et al. PRINCE: A phase III study comparing intermittent docetaxel therapy versus continuous docetaxel therapy in patients with castration-resistant prostate cancer. J Clin Oncol. 2016; 34 (suppl; abstr 5005).

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs